Johnson & Johnson buy UBS Group AG
Summary
This prediction is currently active. With a performance of 4.03%, the BUY prediction by UBS_Group_AG for Johnson & Johnson is trending in the right direction. A total of €3.35 was paid as dividends for this prediction. This prediction currently runs until 01.12.24. The prediction end date can be changed by UBS_Group_AG at any time. UBS_Group_AG has 50% into this predictionJohnson Johnson is a multinational company that focuses on the development, manufacturing, and marketing of a wide range of consumer health products, medical devices, and pharmaceuticals. The company was founded in 1886 and is headquartered in New Jersey, USA. It operates in more than 60 countries and has a diverse portfolio of popular brands including Band-Aid, Tylenol, and Neutrogena. As of 2021, Johnson Johnson has a market capitalization of over $435 billion and is listed on the New York Stock Exchange under the symbol JNJ.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Johnson & Johnson | 1.010% | 1.010% |
iShares Core DAX® | -1.114% | 3.430% |
iShares Nasdaq 100 | 1.816% | 6.911% |
iShares Nikkei 225® | 2.113% | 5.501% |
iShares S&P 500 | 2.038% | 5.327% |
Comments by UBS_Group_AG for this prediction
In the thread Johnson & Johnson diskutieren